logo-loader
viewActinium Pharmaceuticals Inc

Actinium Pharmaceuticals unveils new clinical trial for leukemia with its treatment Actimab-A

The new study addresses whether Actimab A can be used to treat patients who are in remission from acute myeloid leukemia but who still have detectable cancer

Cancer cells
Jason McCarthy, an analyst with Maxim Group, has a Buy rating and US$3 price target

Actinium Pharmaceuticals Inc (OTCMKTS:ATNRW) is opening another clinical trial to test its cancer drug Actimab-A.

This new study will address whether Actimab A can be used to treat patients who are in remission from acute myeloid leukemia but still have detectable minimal residual disease, which means cancer cells exist at low levels and can trigger relapses.

"It will be a significant advancement for acute myeloid leukemia patients if this trial shows the ability to target minimal residual disease and reduce relapse rates," said Dr. Joseph Jurcic, director of the Hematologic Malignancies section and a professor at Columbia University Medical Center, who is leading the new trial.

Read: Maxim Group enthusiastic about Actinium Pharmaceuticals' innovative leukemia drug pipeline

Jason McCarthy, an analyst with Maxim Group who has a Buy rating and US$3 price target on the stock, says the application of Actimab-A to leukemia patients in remission suggests the antibody can be used across the spectrum of acute myeloid leukemia.

“With a highly targeted, low dose, high potency and safer approach, Actimab could improve patient outcomes such as progression-free survival and overall survival,” he adds.

As many as 21,000 patients are diagnosed with acute myeloid leukemia yearly in the US and over 350,000 cases of acute myeloid leukemia exist worldwide.

Actinium’s shares shot up 31.2% to US$0.21 in afternoon trade on the news.

Quick facts: Actinium Pharmaceuticals Inc

Price: 9.68 USD

NYSE:ATNM
Market: NYSE
Market Cap: $131.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals sees record revenue and more strong growth beyond 1Q...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) CEO Ken d’Entremont tells Proactive the specialty pharmaceutical company posted record revenue of C$27.5 million during its fiscal first-quarter thanks to strong sales of its four leading drug products. d’Entremont says he sees because the...

55 minutes ago

2 min read